Govind Srimathveeravalli

first of my name, father of unicorns, bane of cancer cells, lord of lightning, maker of healing devices and teacher of design. Assoc Prof at UMass Amherst.

[Drug Monkey @drugmonkeyblog]

Thinking about this one today. For reasons.

From the Archive: I wonder what happened to that lab? https://t.co/fDcdyy0NZJ via @drugmonkeyblog

[Govind Srimathveeravalli @GovindSLab]

@UpasanaDA Welcome to UMass

[Dr. Anthony Letai @NCIDirector]

I’ve heard concerns about @theNCI funding in FY26—especially about the number of awards issued so far. Here’s some context. 🧵

[Govind Srimathveeravalli @GovindSLab]

@JuliusChapiro Most medical components are built on top of standard/industrial gas/liquid handling ones. McMaster or similar may have tubing that you can repurpose “off label”

[Julius Chapiro @JuliusChapiro]

Courageous and great article from @MSKCancerCenter on Histotripsy published in @cvironco ! Link: https://t.co/ubMPOeRioK

“Patients arrive with predetermined expectations shaped by marketing rather than clinical reality, pressuring physicians
to offer treatments lacking comprehensive validation. Healthcare institutions acquire expensive systems to
remain competitive, even when clinical need may not justify the investment. Resources are diverted toward technologies with limited proven benefit, while established treatments receive diminished attention.”

“Aggressive promotion, driven by commercial interests and capital market pressures, presents theoretical benefits as established advantages. Current histotripsy studies remain predominantly single-center experiences with
limited follow-up. The technology’s purported immunologic effects remain entirely theoretical, yet marketing
materials present these claims with inappropriate certainty. Patients seek "non-invasive" treatments based on promotional materials overstating capabilities while minimising limitations. This marketing-first approach raises
ethical concerns about informed consent and resource allocation.”

[Govind Srimathveeravalli @GovindSLab]

@khademh Wow big move! Best of luck for next steps.

[Govind Srimathveeravalli @GovindSLab]

https://t.co/5nZPCpkmDJ

More FUD around funding for the coming year …

[Govind Srimathveeravalli @GovindSLab]

@drugmonkeyblog Yet paylines have been slashed as though they are following the multiyear mandate. So where’s the money going then?

[Govind Srimathveeravalli @GovindSLab]

@drugmonkeyblog Been tracking this data for nci. Majority of recent ones are single year awards. Is there any way of parsing what payline and council dates are being funded?

[Govind Srimathveeravalli @GovindSLab]

@drugmonkeyblog I read these with great (self interest). I was tracking some of this for NCI. It appears many multi year awards went to ECI. Based on numbers, there’s should be considerable unspent funds remaining with 6 weeks in the FY.

[Govind Srimathveeravalli @GovindSLab]

@jennamueller711 @UMDBIOE @FischellInstUMD @CallaHealth @UMmedschool Congrats! Look forward to seeing the exciting research.

[Govind Srimathveeravalli @GovindSLab]

@BladderCancerUS I did go through the criteria. It did not seem my case was a good fit, I wanted to know if an exception could be made. An email to the contact on the site did not elicit any useful guidance. Ergo the public post on Twitter - which advised me to go read the rfa.

[Govind Srimathveeravalli @GovindSLab]

@PigiLab @PennMedicine @PennRadiology @SIRspecialists @RSNA @SIO_Central @PennMedNews @PennNSG Sweet! Look forward to amazing research from your group.

[Govind Srimathveeravalli @GovindSLab]

@manickam_lab @DuquesnePharm @UTHealthHouston Congratulations, best wishes for B exciting new beginnings.

[Govind Srimathveeravalli @GovindSLab]

@UberIN_Support Sent DM. Appreciate the prompt response!

[Govind Srimathveeravalli @GovindSLab]

@Uber_India wanted to share feedback on a recent trip but the app is restricted on options. Driver showed up just short of the spot, changed status to arrived but kept playing tag when we tried getting into the car. Uber automatically rebooked another taxi.

[Govind Srimathveeravalli @GovindSLab]

Driver then stops for pick up and asks me to cancel the other ride as he can take me to destination. When I boarded asked me to pay cash for the original amount. As uber only allows feedback for completed rides, there’s no way of providing feedback on this person with app. #scam

[Govind Srimathveeravalli @GovindSLab]

@mkoeris @DARPA goats as mobile medicinal factories via milk

[Govind Srimathveeravalli @GovindSLab]

@abandopa I am not in India but am very much involved in medtech startups here. Would love to be part of this for. Please let me know if I can join.